2nd Annual Microbiome Discovery and Development Congress

Oxford Global is proud to present the 2^nd Annual Microbiome Discovery and Development Congress, taking place on the 7-8^th June 2018 in Berlin, Germany. The conference showcases world-class senior industry experts presenting case studies on the most exciting issues in the microbiome field, covering novel strategies in microbiome research, the latest therapeutic trends, and the challenges and opportunities involved in commercialising microbiome therapeutics.

View Agenda: http://bit.ly/2BOsODK

The congress will cover 2 areas focusing on:

• Novel Strategies & Technologies for Microbiome Drug Discovery
• Therapeutic Potential of the Microbiome
• New for 2018! Workshop on commercialising microbiome therapeutics.

Further sessions will focus on subjects including bioinformatics, translational modelling, genomic approaches, IP concerns, investment in the microbiome, the gut-brain axis and autoimmune disorders. The two-day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions.

2018 Microbiome Webinar:     
Microbiome-Directed Therapeutics to tackle metabolic disorders      
Hosted by Sandrine Claus, Chief Scientific Officer, LNC Therapeutics      
Register for Free Now: http://bit.ly/2j0IqvO

2018 Microbiome Discovery & Development Congress Confirmed Speakers Include:

Colette Shortt, Regulatory Director, Global Franchise Organisation
J&J Consumer

Lionel Breton, Global Director of Open Research
L’Oreal

Patrice Garnier, Chief Executive Officer
AMAbiotics

Veronika Oudova, Chief Executive Officer
S-Biomedic

Catherine O’Neill, Chief Executive Officer
SkinBio Therapeutics

Nader Yaghoubi, Chief Executive Officer
Symbiotix Biotherapies

Sanja Selak, Chief Executive Officer
Origimm

Xavier Duportet, Chief Executive Officer
Eligo Bioscience

Ross O. Youngs, Founder and Chief Executive Officer
Biosortia Pharmaceuticals

Sandrine Claus, Chief Scientific Officer
LNC Therapeutics

Alexander Sulakvelidze, Executive Vice-President and Chief Scientific Officer
Intralytix

Nikole Kimes, Founder and Vice President
Siolta Therapeutics

Imke Mulder, Research Director
4D Pharma

Jean-Francois Dubuisson, Pharmaceutical Development Project Manager
MaaT Pharma

Ling-Yang Hao, Principal Scientist
J&J

Tom Parks, Director of Product Development
Osel Inc.

James McIlroy, Chief Executive Officer
Enterobiotix

Sonia Timberlake, Director of Data Science
Finch Therapeutics

For more information about our programme and to register for the congress, please contact Guillaume Alonso at g.alonso@oxfordglobal.co.uk